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H UMAN diploid fibroblasts have a finite replicative life span and have been widely used to study biological aging (1, 2) . The cumulative mean population doubling (MPD) before the senescent arrest of human diploid fibroblasts is universally proportional to the age of the donor. The phenotype of late-passage (senescent) fibroblasts is well described and characterized by altered morphology, telomere shortening, apparent resistance to apoptosis, a general dysregulation of coordinated process, and loss of responsiveness to mitogens (3, 4) . The human fibroblast model has been a valuable tool for explaining the mechanism underlying cellular aging observed in situ (5) . One of the important areas of research includes study of changes in mitogen-activated protein kinase (MAPK) activation as related to low-density lipoprotein receptor (LDLr) expression. A close correlation between LDLr expression and activation of one of the components of MAPK, extracellular signal-regulated kinase 1/2 (ERK-1/2), has been shown in several human cultured cell lines (6-8) but it has not been well documented in fibroblasts. The receptor-dependent cellular LDLr pathway appears to be important for the degradation of low-density lipoprotein (LDL) (5) , and it is well described in fibroblasts (10) (11) (12) . The major function of LDLr is to protect against atherosclerosis. This protection is achieved through the high affinity of LDLr. Moreover, because LDLr is subject to regulation, cells that use the receptor mechanism to obtain cholesterol are protected from excessive cholesterol accumulation (9) . An earlier report has shown that human diploid fibroblasts at late passage (old, senescent) have more cholesterol than early-passage (young), and one of the reasons for this is due to high level of caveolin-1 expression in these cells (13) . Caveolin-1 expression directly correlates with MAPK signaling. In human diploid fibroblasts, overexpression of caveolin-1 suppresses ERK-1/2. Other reports have demonstrated changes in cholesterol metabolism during cellular senescence, and this is related to the deficiency of signaling in these fibroblasts (14) .
MAPK mediates extracellular signals that regulate cell growth, differentiation, survival, and death (15, 16) . At present, three major subfamilies of mammalian MAPK pathways have been studied in detail. All three MAPK are activated by phosphorylation of tyrosine and threonine residues and catalyzed by the dual specificity of MAPK. The ERK-1/2 pathway is strongly activated by mitogenic signals. Moreover, activated ERK-1/2 promotes cell proliferation. It has been further demonstrated that active ERK stimulates DNA synthesis (17) and enhances the activity of AP-1 transcription factor through Elk-1 and c-fos (18) (19) (20) . Other members of the MAPK, SAPK/JNK1/2/3, and p38 MAPK (p38a, p38b, p38c, and p38d), are primarily activated by proinflammatory cytokines (21) , cellular stress, tumor necrosis factor-a, and ultraviolet irradiation (22, 23) . Upstream activators of these three kinases may function both specifically and with cross-specificity, resulting in activation of more than one MAPK. For example, in response to epidermal growth factor, ERK is activated as much as 20-fold, while JNK (c-jun NH 2 terminal kinase) is activated up to 6-fold (24) (25) (26) . The nuclear translocation of MAPK appears to be a prerequisite for proper cellular response (27) . ERK-1/2 MAPK nuclear translocation has been shown to be essential for growth factor-induced DNA replication and cell transformation (28, 29) .
Interleukin-1ß (IL-1ß), a central proinflammatory mediator, induces the expression of multiple genes involved in the inflammatory process and malignant diseases often associated with abnormal cholesterol metabolism (30) (31) (32) (33) (34) (35) (36) . The signaling mechanism leading to the stimulation of LDLr expression by IL-1b has been elucidated in HepG2 cells (6) , but this mechanism is not well described in fibroblasts. However, it is known that growth stimuli such as insulin and platelet-derived growth factor augment LDLr activity in fibroblasts (37, 38) .
In this study, we investigated changes, in the induction of LDLr expression and stimulation of MAPK in early-and late-passage human diploid fibroblasts, after IL-1 stimulation. In addition, we investigated the activation and localization of ERK-1/2 in these cells, because the ERK pathway provides a critical link between the extracellular environment and cellular nuclear regulatory changes. Our results demonstrated that early-and late-passage fibroblasts respond differently to the cytokine. Maximum expression of LDLr mRNA was seen after 16 hours of cytokine treatment in early-passage cells, while in late-passage cells it was between 16 and 24 hours, in addition, IL-1ß-mediated induction was fourfold lower in late-passage cells compared with early-passage cells. Late passage cells required more time to reach the maximum stimulation of ERK, and the stimulation-induced ERK-1/2 molecules in late-passage cells were lower than in early-passage cells under similar conditions when compared with their corresponding controls. On the other hand, late-passage cells showed higher amounts of stress-activated MAPK p46 JNK1 . Taken together, our results demonstrate an association between decline in nuclear translocation of ERK-1/2 and induction of LDLr following IL-1b treatment in early-and latepassage fibroblasts. Our results also suggest that LDLr expression in these cells is partly controlled by MAPK.
METHODS

Cell Culture and IL-1b Stimulation
Fibroblasts used in this study were of strain A8; they were obtained from the foreskin of a 26-year-old healthy male donor and established by Dr. S. Goldstein (39) . They were kindly provided to us by Dr. Beata Lecka-Czernik (Department of Geriatrics, University of Arkansas for Medical Sciences) at 17 MPD. A8 cells have a maximum life span of 68 MPD (40) , after which they become senescent. In all experiments, early-passage fibroblasts were in their first third of replicative life span when they required ,6 days to become confluent after a 1:8 split. Late-passage fibroblasts had completed 75%-90% of the life span and they grew more slowly, requiring 6-8 days to become confluent after 1:4 split. Early-(;20 MPD) and late-passage (;60 MPD) fibroblasts were grown in monolayers in 225 cm 2 stock flasks containing 25 ml of growth medium, which consisted of Eagle's minimum essential medium (BioWhittaker, Walkersville, MD), 24 mM NaHCO3, vitamin 1%, nonessential amino acid 0.1%, glutamine-1.2%, and antibioticantimycotic-1.2% supplemented with 10% fetal bovine serum (FBS). For experiments, confluent monolayers of cells from the stock flasks were dissociated with 0.25% trypsin and 1 mM of ethylenediaminetetraacetic (EDTA) acid solution. For each experiment, 7 3 10 5 cells were plated on day 0 in 150 mm 2 culture plates containing 10 ml of growth medium with 10% FBS. On day 2, cells were refed with fresh medium. On day 5, when cells were about 60%-70% confluent, they were changed to a media containing 0.5% FBS, and 24 hours later they were treated with 10 ng/ ml IL-1b (this and other chemicals were obtained from Sigma, St. Louis, MO), for the indicated time. For inhibitor studies, cells were pretreated for 1 hour with MAPK inhibitors, PD098059 (Calbiochem Biosciences, Inc., La Jolla, CA) or UO126 (Cell Signaling Technology, Inc., Beverly, MA).
RNA Isolation
RNA was isolated from early-and late-passage cells utilizing the RNeasy kit (Qiagen, Inc., Valencia, CA). Briefly, cells were washed with phosphate buffered solution (PBS), trypsinized, and centrifuged at 300 3 g for 5 minutes. Pellets were collected and immediately dissolved in RLT lysis buffer (Qiagen) containing ß-mercaptoethanol by pipetting up and down. Lysates were immediately processed for RNA preparation. The complete process was followed according to the instructions from Qiagen.
cDNA Probes
The cDNA probes were made by polymerase chain reaction amplification of a 400-base pair (bp) region upstream of the human LDLr cDNA, cloned in plasmid pcDV1 (ATCC #39966) using the sense, 59-CAG GAC GAG TTT CGC TGC CAC G-39, and antisense, 59-GCA GTT TCC ATC AGA GCA CTG-39, primers. The fragment was labeled with (a-32 P)dCTP (ICN Biomedicals, Irvine, CA) by random priming (Megaprime DNA Labeling System, RPN1604, Amersham Biosciences, Piscataway, NJ), purified through QIA quick silica gel spin column (Qiagen), and denatured. High specific activity probes were used for hybridization.
Northern Blot Analysis
Twenty lg of RNA from each sample was denatured at 658C for 15 minutes in sample denaturing loading buffer. The RNA was then subjected to overnight electrophoresis through a 1% agarose and 6.5% formaldehyde gel at 20 V in 20 mM 13 MOPS (20 mM 3-[N-morpholino propanesulfonic acid], 5 mM sodium acetate, and 1 mM EDTA acid [EDTA], pH 7.0) as a running buffer. The RNA was transferred to Zetaprobe GT nylon membrane (Bio-Rad Laboratories, Hercules, CA) by capillary blotting in 10 3 sodium saline citrate (SSC) and ultraviolet cross-linked with Stratalinker (Stratagene, La Jolla, CA). The blots were blocked for 1 hour at 688C in express-hyb hybridization solution (Clontech Laboratory, Inc., Palo Alto, CA) and hybridized at 688C for 1 hour in a hybridization chamber (Thermo Hybaid, Franklin, MA) in fresh solution containing a human 400 bp LDLr probe. Membranes were rinsed with 0.2XSSC (15 mM sodium citrate and 150 mM NaCl; pH 7.0) and 0.05% sodium dodecyl sulfate (SDS) at room temperature for 30 minutes with two changes of wash buffer. Membranes were then washed with 0.1 3 SSC and 0.1% SDS for 40 minutes at 608C and 20 minutes at 658C with continuous agitation and several changes of wash buffer. The values were corrected for equal RNA loading by stripping each blot in 0.5% SDS for 10 minutes in boiling water, blocked as above, and rehybridized with a 32 P-labeled 800 bp Eco R1 fragment from human ribosomal protein cDNA (ribosomal S3, a generous gift from Piotr Zimniak, PhD, University of Arkansas for Medical Sciences at Little Rock). Bands were visualized by exposing the membranes to storage phosphor screen. The intensity of each band and background were quantified with Image Quanta program (Molecular Dynamics, Inc., Sunnyvale, CA).
Preparation of Whole-Cell Lysate
Following treatment with IL-1ß as described above, cells were washed with ice-cold 13 PBS and lysed with RIPA buffer (13 PBS, 1% nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS with freshly added protease and phosphate inhibitors) on ice. Cells were collected and homogenized in a hand homogenizer for 5 seconds, passed through a syringe fitted with a 21-gauge needle, and incubated on ice for 40 minutes. Cell lysates were microcentrifuged at 10,000 3 g at 48C for 10 minutes, the supernatant was collected, and protein was estimated by the Bradford method (41) . Equal amounts of protein were used to run the SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
Western Blot Analysis
SDS-PAGE was carried out on 12% separating gel. Equal amounts of protein were loaded on each lane. Fractionated protein was electroblotted onto nitrocellulose membranes at 100 V for 1 hour at 48C. Membranes were blocked in 5% (w/v) nonfat dry milk in Tris-buffered saline and Tween 20 (TBST) (20 mM Tris-HCl, pH 7.6; 137 mM NaCl, and 0.2% [v/v] Tween20), washed five times (5 min each) with TBST, and probed with primary antibodies. Antiphosphoindependent antibodies of ERK-1/2, p46/54 JNK , and p38 MAPK , diluted 1:2000 in TBST containing 5% bovine serum albumin, were incubated at room temperature for 1 hour with gentle shaking. Phosphospecific antibodies were diluted 1:1000 and incubated with membrane overnight at 48C with gentle shaking. After proper washings, membranes were incubated with horseradish peroxidase-coupled anti-IgG (secondary antibody, dilution 1:3000) for 1 hour. All antibodies were purchased from Cell Signaling Technology. Enhanced chemiluminescence (ECLþ, Amersham Biosciences) and fluorescence detection were used as per manufacturer's instructions for visualization of the bands. They were quantified on a Strom 860 Imager (Molecular Dynamic, Inc., Sunnyvale, CA).
Preparation of Cytoplasmic Fraction and Nuclear Fraction and Translocation
Semiconfluent cultures of early-and late-passage cells were treated with 10 ng/ml of IL-1b for 10, 30, and 60 minutes. Cytoplasmic and nuclear fractions were prepared via the method used by Levkau and colleagues (42) and Boyle and colleagues (43) , with minor modifications. In brief, treated cells were trypsinized, centrifuged at 500 3 g for 10 minutes at 48C, washed twice by resuspending the pellets in ice-cold 13 PBS, and centrifuged at 500 3 g for 10 minutes at 48C. The supernatant was discarded, and the cell pellets were lysed in buffer (150 mM NaCl, 150 mM sucrose, 20 mM Hepes [pH 7.4], 5 mM KCL, 2 mM DTT, 1 mM MgCl 2 , 0.05 mM CaCl 2 , 0.1% digitonin, 0.5 mM phenylmethylsulfonyl fluoride, 1 lg/ml aprotinin, and 1 lg / ml leupeptin) by gentle mixing with a pipette and incubation on ice with gentle agitation for 30 minutes. Cell suspensions were centrifuged at 1000 3 g for 10 minutes at 48C. The supernatant was collected as a cytoplasmic fraction. The pellets obtained from cytoplasmic extraction were suspended in lysis buffer, incubated on ice with gentle mixing for 60 minutes, and centrifuged at 30,000 3 g for 30 minutes at 48C. The clear supernatant contained a nuclear fraction. Protein was quantified as above. Equal amounts of protein were loaded on each lane, and SDS-PAGE was carried out, followed by immunoblotting. Membranes were incubated with antiphosphoindependent and antiphosphodependent ERK-1/2 MAPK primary antibodies followed by incubation with a peroxidase-linked secondary antibody. Immunoreactive proteins were detected with enhanced chemiluminescence according to the supplier's protocol.
Statistical Analysis
Values are expressed as the arithmetic mean 6 1 standard error of the mean (SEM). Analysis of the data was performed using a one-tailed Student's t test. Differences in means having p , .05 were considered to be statistically significant.
RESULTS
Influence of IL-1b on LDLr mRNA Expression in Serially Passaged Normal Human Fibroblasts
Early-and late-passage cells were incubated in the presence of 10 ng/ml of IL-1b for various periods of time up to 32 hours. Northern blot analysis of 10 studies demonstrated that expression of LDLr mRNA reached peak stimulation 16 hours after IL-1b treatment in early-passage cells (all studies), while in late-passage cells, the peak was attained at 16 hours in 7 studies and 24 hours in 3 studies, after treatment, and the fold inductions were almost similar at 16 hours and 24 hours in late-passage cells ( Figure 1A ). Increases in LDLr mRNA levels were significantly different, 6.8-and 3-fold in early-and late-passage cells, respectively (p , .001, Figure 1B ). Enhanced LDLr mRNA expression in early-passage cells dropped to 1.90-and 1.86-fold after 24 hours and 32 hours, respectively. However, in latepassage cells, the LDLr mRNA level remained elevated approximately 2.89-fold even at 24 hours and gradually decreased to 1.49-fold by 32 hours ( Figure 1B) . Earlypassage cells showed a slightly elevated basal LDLr mRNA level over late-passage cells, but the difference was not significant.
Changes in MAPK Activation in Early-Passage and Late-Passage Fibroblasts by IL-1b In the signal transduction cascade, ERK MAPK is the final regulatory step to activate transcription of genes involved in cell proliferation. We measured the total activated (phospho) ERK-1/2 in response to stimulation by 10 ng/ml of IL-1b in early-and late-passage human fibroblasts. Western blot analysis of total cell lysate of both types of fibroblasts showed that the basal level of total ERK-1/2 was threefold higher in late-passage fibroblasts compared to the earlypassage fibroblasts (Table 1) . Stimulation by IL-1b did not change total ERK-1/2 appreciably in either kind of cells. To investigate the effect of IL-1b stimulation on the activation of ERK-1/2, we measured levels of phospho ERK in these fibroblasts. As observed with total ERK, the basal phospho ERK level was also higher (twofold, p , .02) in latepassage cells. Stimulation of late-passage cells by IL-1b resulted in weak induction of phospho ERK, requiring 20 Lysates were prepared from fibroblasts, and, using appropriate antibodies, Western blots were performed. Intensities of bands were corrected for loading by reprobing the membrane with b-Actin antibody. In each study, the lysates from early-and late-passage cells have been included as a pair. The numbers of observations for each pair are given within the brackets.
MAPK ¼ mitogen-activated protein kinase; ERK ¼ extracellular signalregulated kinase 1/2; JNK ¼ c-jun NH 2 terminal kinase. Figure 2 . Activation of phosphorylated extracellular signal-regulated kinase 1/2 (ERK-1/2) in early-and late-passage fibroblasts following interleukin-1-beta (IL-1b) treatment. Cells were plated exactly the same as described in Methods and treated with 10 ng/ml of IL-1b for indicated intervals. After these intervals, cells were washed with 13 PBS (phosphate-buffered saline) and lysed in RIPA (ristocetin-induced platelet agglutination) buffer. SDS (sodium dodecyl sulfate) sample buffer was added to each sample. Equal amounts of whole-cell lysate were separated by 12% gels. Phosphorylation levels of ERK-1/2 were analyzed by Western blotting using phospho-specific antibodies, following electrotransfer of total proteins to a nitrocellulose membrane. Values are expressed as fold inductions in early-passage (circles and solid line) and late-passage (triangles and dashed line) fibroblasts above respective controls. The insert shows the bands of ERK-1/2 and phospho ERK-1/2 on representative blots. Mean 6 SEM (standard error of mean) were derived from 7 separate experiments, and bands were normalized for loading by reprobing the membrane with b-Actin antibody. *p , .02. minutes to reach a maximum level of 1.9-fold ( Figure 2 ). However, stimulation of early-passage cells by IL-1b was stronger (2.8-fold), and the induction of phospho-ERK-1/2 peak quantity required a relatively shorter time (10 min, Figure 2 ).
In the next study, Western blot analysis was performed with total cell lysate using phospho and total antibodies for p46/54 JNK1/2 and p38 MAPK , with and without stimulation by IL-1b. Total basal JNK1 was significantly higher (1.6-fold; p , 0.02) in the late-passage fibroblasts, while basal levels of JNK2 were similar in early-and late-passage cells ( Table  1 ). In both types of cells, phospho p46/54 JNK1/2 increased after treatment with IL-1b by twofold, but in both instances, early-passage cells required 20 minutes to attain the maximum induction, whereas late-passage cells reached the maximum at 10 minutes ( Figure 3A and B ). p38 MAPK showed a different pattern in these cells. Total basal p38 was significantly higher in early-than in late-passage cells ( Table 1 ). Maximum induction of phospho p38 MAPK was observed in both cell types within 10 minutes after IL-1b treatment (Figure 4 ). Thus, our results revealed that after IL-1b treatment, a rapid phosphorylation of ERK-1/2, JNK-1/2, and p38 occurred in both types of cells. However, the time needed by these three MAPK to reach maximum phosphorylation was different in early-and late-passage cells.
Nuclear Translocation of Activated ERK-1/2 in Early-Passage and Late-Passage Fibroblasts After IL-1b Stimulation
Nuclear translocation of MAPK has been shown to be essential for growth factor-induced DNA replication and appears to be a prerequisite for proper cellular response. Because ERK-1/2 required more time to reach the peak value in late-passage cells, in our next study, we attempted to measure the nuclear translocation of ERK-1/2. As discussed previously, we observed a higher level of total basal ERK-1/2 in total cell lysate of late-passage cells. The ERK-1/2 nuclear translocation pattern in response to IL-1b was different in early-versus late-passage cells. We found that despite proper activation in late-passage cells, the ERK-1/2 pool was equally distributed in the cytoplasmic and nuclear fractions, while most of the ERK-1/2 pool in earlypassage cells was observed in the cytoplasmic fraction after IL-1b stimulation ( Figure 5 ). To determine whether the inactive ERK molecules that accumulated in late-passage fibroblasts were competing with active ERK-1/2 molecules for nuclear translocation, we used the phosphorylated ERK-1/2 antibody to detect the active form of this protein following IL-1b activation in early-and late-passage cells. As shown in Figure 5 , Western blot analysis showed that IL-1b treatment resulted in dramatically increased accumulation of phosphorylated ERK-1/2 molecules in the nuclear fraction of early-passage fibroblasts (by 10 min). However, the nuclear accumulation of ERK-1/2 in late-passage cells was slow and peaked 30 minutes poststimulation, which was reduced to the basal level within 60 minutes.
LDLr Expression in Fibroblasts Is Mediated Through ERK-1/2 Activation
To study the involvement of ERK-1/2 in LDLr expression, we used ERK-1/2 MAPK selective inhibitors, PD098059 and UO126, both of which block MEK phosphorylation and subsequent activation of ERK-1/2. Figure 6 shows that both PD098059 (5-50 lM) and UO126 (2.5-10 lM) inhibited the IL-1b-induced ERK-1/2 activation in early-passage fibroblasts. Of these inhibitors, UO126 was more inhibiting to ERK-1/2 activation than PD098059. Neither inhibitor affected activation of p46/54 JNK1/2 and p38 MAPK (Figure 6 ). PD098059 treatment did not affect total ERK-1/2 protein expression, as shown by Western blots performed with the phosphorylation-independent ERK-1/2 antibody, whereas UO126 slightly affected total ERK-1/2 protein expression (data not shown). In our next study, we examined the effect of treatment with the same two inhibitors (PD098059, 50 and 100 lM; UO126, 5 and 10 lM) on LDLr expression after IL-1b treatment. As shown in Figure 7 , inhibitions of 43%-73% (with PD098059) and 68%-82% (with UO126) were observed in LDLr mRNA expressions for the doses given above, respectively. This suggested an essential requirement, in part, for the ERK-1/2 signaling cascade in IL-1b-induced LDLr expression.
DISCUSSION
In the present study, we have demonstrated for the first time a difference in the activation time and extent of expression for IL-1b-stimulated ERK, JNK, p38, MAP-Kinase, and LDLr in early-and late-passage fibroblasts. We report that IL-1b treatment at a dose of 10 ng/ml significantly stimulates MAPK and LDLr gene expression in these cells. Stimulation of MAPK is quick and, in most cases, takes 10 minutes in early-passage cells, whereas IL-1b treatment in late-passage cells leads to a 2-, 2.5-, and 1.9fold induction of JNK1/2, p38 MAPK , and ERK-1/2, respectively, within 10-20 minutes. We have focused primarily on the expression of LDLr and MAPK in serially passaged fibroblasts and the correlation between MAPK activation and LDLr expression in these cells, both after IL-1b treatment. To confirm the role of ERK-1/2 in IL-1binduced LDLr expression in early-and late-passage fibroblast, we used the MAPK inhibitors PD098059 and UO126 to suppress ERK-1/2 activation in early-passage cells. As shown in the Results section ( Figures 6 and 7) , pretreatment of cells with PD098059 or UO126 inhibits IL-1b-induced ERK-1/2 activation and LDLr expression in fibroblasts without affecting the phosphorylation of p46/ p54 JNK 1/2 or p38 MAPK (Figure 6 ).
IL-1b, a well-known cytokine, triggers a signaling cascade that leads to activation of MAPK and that has been extensively used to induce LDLr and MAPK in different cell lines (6, 21, 44, 45) . Other mediators, including several growth factors, have been found to up-regulate LDLr activity, presumably by their mitogenic activity. In our study, induction time in LDLr transcript expression was similar to MAPK in young and old cells. The kinetics of LDLr induction and ERK-1/2 activation are closely related in both cell types. Correlation between LDLr expression and ERK-1/2 activation has already been shown in several human cultured cell lines (6) (7) (8) . Numerous studies have demonstrated that the proliferative capacity of cells declines with aging (46) . Growth activation of quiescent cells leads to enhanced LDLr expression at the cell surface via LDLr gene transcription (47) . Our results show decreased expression of LDLr in late-passage cells after IL-1b treatment, which is related to the growth receptors and proliferative capacity of cells. We have also observed increased ERK protein and baseline phosphorylated ERK in late-passage cells compared with early-passage cells. Consequently, fold induction of ERK is decreased and its Figure 2 were analyzed with the phospho-specific anti-p38 MAPK antibody. The Western blotting protocol was the same as that in Figure 2 . Values were expressed as the fold induction in antiphospho-p38 MAPK compared to noninduced cells. The insert shows the bands of p38 and phospho p38 on representative blots. Mean 6 SEM (standard error of mean) were derived from 5 separate experiments. All bands were normalized for loading by reprobing the membrane with b-Actin antibody.
activation is prolonged after IL-1b treatment in late-passage cells. Thus in late-passage cells, a higher basal phosphorylated ERK-1/2, lower inducibility, and delayed translocation of ERK-1/2 are seen. Phosphorylated ERK-1/2 levels are supposed to indicate proliferative status. However several reports have shown that the quantity of nuclear ERK and the length of time ERK spends in the nucleus determine whether ERK signaling is proliferative or antiproliferative [reviewed in (48) ]. It has been shown in hamster fibroblasts that the phospho ERK protein pool, accumulated in the nucleus, is inactivated with time and remains in the nucleus in an inactive form (49) . In hepatocytes, prolonged activation of the phospho ERK level inhibits DNA synthesis (50) . An altered profile of the transcription factor, which binds with DNA to initiate the synthesis and cell pro-liferation, is known to decrease in human late-passage fibroblasts (51) . Thus, further investigation on this line is needed to determine whether phospho ERK-1/2 present in late-passage cells are still active and functional.
The ERK MAPK group regulates multiple targets in response to growth factors via a RAS-dependent mechanism. In contrast, JNK activates the transcription factor c-Jun in response to proinflammatory cytokines and following exposure of cells to several forms of environmental stresses. The p38 MAPK that shares sequence similarity with other MAPK pathways is also activated by proinflammatory cytokines and environmental stress. The mechanism of p38 MAPK activation is mediated by dual phosphorylation on threonine-180 and tyrosine-182. Thus, p38 MAPK , like JNK, may be regulated in part by a stress-activated signal transduction pathway. However, in our experiments, earlyand late-passage fibroblasts show differences in the time course and extent of activation in p38 MAPK and JNK, indicating that these pathways may be distinct. Indeed, p38 MAPK and JNK may represent parallel stress-activated signal transduction pathways (52) . JNK and p38 MAPK may activate a number of transcription factors reported to contribute to c-jun promoter activity (53) .
In most cell types, the mitogenic signal is relayed from the cytoplasm to the nucleus by nuclear translocation of phosphorylated ERK-1/2, resulting in phosphorylation and activation of a range of transcription factors (54) . Thus, subcellular localization of ERK-1/2 is an important determinant of their functions. ERK-1/2 is activated and translocated into the nucleus, while it is largely cytoplasmic in unstimulated cells (55, 56) . Mitogenic capacity and responsiveness to the mitogen is lost in aging and leads to cellular senescence (57) . In view of the importance of the ERK pathway to cellular proliferation and response to growth factors, it was in our interest to confirm the notion of delayed activation of IL-1b-induced MAPK in late-passage fibroblasts. We examined the ERK-1/2 nuclear translocation in these cells, which is vulnerable to aging in a variety of experimental models in vivo and in vitro [reviewed in (57) ]. We used 10 ng/ml of IL-1b for 10, 30, and 60 minutes to activate the cells. This enabled us to demonstrate a very clear difference in the movement of phosphorylated ERK-1/ 2 from the cytoplasm to the nucleus in these cells. Earlypassage cells showed a rapid entry of phosphorylated ERK-1/2 to the nucleus. However in late-passage cells, nuclear translocation of active ERK-1/2 required 30 minutes. From these results, we concluded that IL-1b triggered a rapid entry of phosphorylated ERK-1/2 MAPK into the nucleus of early-passage cells, but entry was delayed in late-passage cells. In our experiments, the ERK-1/2 baseline protein level in whole-cell lysates of late-passage cells was higher than in early-passage cells, as reported by others (26, 53) , and in our results, late-passage cells also showed more basal phosphorylated ERK1/2, possibly due to higher constitutive MEK in late-passage cells (58) . Moreover, fold induction revealed a decreased ERK-1/2 activation in late-passage cells. It is still unclear whether the accumulation of unphosphorylated ERK molecules in late-passage cells affects the nuclear translocation of phosphorylated molecules. Adachi and colleagues (59) recently found that nuclear translocation of ERK occurs via an active transport mechanism requiring formation of an ERK dimer. Furthermore, it has been shown that, although phosphorylation is important for dimer formation, microinjected phosphorylated ERK-1/2 molecules could dimerize with unphosphorylated molecules, resulting in translocation and accumulation of inactive ERK proteins in the nucleus (55) . This is consistent with our results that showed equal distribution of total ERK-1/2 in cytoplasmic and nuclear fractions of late-passage cells. Alternatively, the nuclear Figure 6 . Effect of mitogen-activated protein kinase (MAPK) inhibitors on phosphorylation of extracellular signal-regulated kinase 1/2 (ERK-1/2), p46/ 54 JNK (c-jun NH 2 terminal kinase), and p38 MAPK in early-passage fibroblasts after stimulation with interleukin-1-beta (IL-1b). Cells were grown as described in Methods and were treated with 10 ng/ml of IL-1b for 10 minutes in the presence or absence of PD098059 or UO126, added 1 hour before IL-1b. Cell extracts were prepared, and equal amounts were loaded onto gels and immunoblotted with antiphospho-ERK-1/2, antiphospho-46/54 JNK , or antiphospho-p38 MAPK antibodies. All bands were normalized for loading by reprobing the membrane with b-Actin antibody. The blots shown are representative of 3 separate experiments. import of phosphorylated ERK molecules may not be inhibited, but ERK may be rapidly dephosphorylated by nuclear phosphatase (s), in late-passage cells, as shown by other researchers (47) .
Our report demonstrates that IL-1b activates the MAPK cascade and stimulates LDLr gene expression at the transcriptional level in early-and late-passage fibroblasts. Inhibitor studies suggest that ERK-1/2 activation and LDLr expression in these cells are correlated. It also suggests that MAPK activation is not the only factor to induce the LDLr expression in early-and late-passage fibroblasts, as our results showed that less LDLr expression, more basal and less activation of ERK in late-passage cells is more likely the age effect. It remains to be determined whether the activation of ERK-1/2 MAPK is a basis of the regulation of LDLr gene in these cells. As aging is associated with an increased risk for atherosclerosis, our studies could provide a potential mechanism for reduction in serum lipid levels that contribute to changes in cholesterol homeostasis and lead to atherosclerosis. Furthermore, our report could create an opportunity to design novel therapeutic compounds that would be useful in treating inflammatory disorders in aging.
